18 F]Flubatine was selected for clinical imaging of α 4 β 2 nicotinic acetylcholine receptors because of its high affinity and appropriate kinetic profile. A fully automated synthesis of (À)-[ 
Introduction
Dysfunction of the cholinergic neurotransmitter system is one factor contributing to cognitive decline in neurodegenerative disorders such as Alzheimer's disease. 1 Reflecting this, noninvasive positron emission tomography imaging of cholinergic brain function is an extremely active research arena. Radiopharmaceuticals that permit measurement of the vesicular acetylcholine transporter, acetylcholinesterase activity, and both muscarinic and nicotinic acetylcholine receptors (nAChRs) find widespread clinical application (for recent reviews, see Refs 2-7 [2] [3] [4] [5] [6] [7] ). We currently evaluate acetylcholinesterase activity by using 1-[ 11 C] methylpiperidin-4-yl propionate 8 and the vesicular acetylcholine transporter with (2R,3R)-5-[
18 F]fluoroethoxy-benzovesamicol. 9 With the goal of expanding our understanding of cholinergic dysfunction in our clinical population, we were desirous of also making a radiopharmaceutical available for clinical imaging of nAChRs. Many radiopharmaceuticals for quantification of nAChRs have been reported to date (reviewed in Refs 2-7 [2] [3] [4] [5] [6] [7] ), but we focused our attention on [ F ]flubatine in 2% radiochemical yield and utilized an ethyl carbamate-protected bromo precursor, specialized microwave synthesis equipment, iodotrimethylsilane-mediated carbamate deprotection, and two semi-preparative HPLC purifications including a chiral one as a racemic precursor was employed. [14] [15] [16] This was not readily adaptable to clinical radiopharmaceutical production in our positron-emission tomography (PET) center, and so, we have built upon this initial work and capitalized on the enantiomerically pure Boc-protected trialkyl ammonium iodide precursor now commercially available to simplify the synthesis. We report a fully automated, high yielding radiosynthesis of (À)-[ 18 F]flubatine on a standard automated fluorine-18 synthesis module. Acid-mediated deprotection of the Boc group and purification of the product by using semipreparative HPLC with a standard C18 column make it suitable for production of clinical doses. Completion of this synthesis optimization in our laboratory coincided with reports of an extensive precursor evaluation study by Fischer and colleagues, 19 which reported improved yields (up to 60% by using manual radiochemical methods although no radioactivity amounts were specified) and also concluded that the Boc-protected trialkyl ammonium iodide is the precursor of choice for synthesizing (À)-[ 
Materials and methods

General considerations
Unless otherwise stated, reagents and solvents were commercially available and used without further purification: (À)-flubatine precursor and reference standard were purchased from ABX Advanced Biochemicals; potassium carbonate, sodium hydroxide, and hydrochloric acid were purchased from Sigma Aldrich; kryptofix-2.2.2, acetonitrile, and dimethyl sulfoxide (DMSO) were purchased from Acros Organics; ethanol for HPLC was purchased from Decon Laboratories, Inc.; and sodium chloride, 0.9% United States Pharmacopeia (USP), and sodium phosphates for injection, USP, were purchased from Hospira. Other synthesis components were obtained as follows: sterile filters were obtained from Millipore, sterile product vials were purchased from Hollister-Stier, and QMA-Light Sep-paks were purchased from Waters Corporation. Sep-Paks were flushed prior to use: 10 mL of NaHCO 3 -10 mL of deionized water-10-mL ethanol-10 mL of deionized water.
Synthesis of (À)-[ 18 F]flubatine
To prepare (À)-[ 18 F]flubatine, we configured a General Electric TRACERlab FX FN synthesis module as previously described 20 and loaded as follows: Vial 1, potassium carbonate (3.5 mg) in deionized water (0.5 mL); Vial 2, kryptofix-2.2.2 (10-15 mg) in acetonitrile (1 mL); Vial 3, (À)-flubatine precursor (1 mg) in DMSO (0.6 mL); Vial 4, 1-M HCl (1 mL); Vial 5, 0.5-M NaOH (2 mL); product collection vial, 0.9% sodium chloride for injection (USP, 3.9 mL) and sodium phosphates for injection (USP, 0.1 mL).
[ Fluoride was then eluted into the reaction vessel by using aqueous potassium carbonate (3.5 mg in 0.5 mL of water). The solution of kryptofix-2.2.2 (10-15 mg in 1 mL of acetonitrile) was then added to the reaction vessel, and the [ 18 F]fluoride was dried by evaporating the water-acetonitrile azeotrope. Evaporation of the azeotrope was achieved by heating the reaction vessel to 80°C and drawing full vacuum for 4 min. After this time, the reaction vessel was cooled to 60°C and subjected to both an argon stream and a vacuum draw simultaneously for another 4 min. The solution of (À)flubatine precursor (1 mg) in DMSO (600 μL) was added to the dried [
18 F] fluoride, and the reaction was heated to 120°C with stirring for 10 min. Subsequently, the reaction mixture was cooled to 80°C, followed by the addition of 1-M HCl (1 mL) and then maintained at 80°C with stirring for an additional 5 min to remove the Boc group. The reaction mixture was then cooled to 50°C, quenched with 0.5-M NaOH, and purified by semi-preparative HPLC (column, Phenomonex Luna C18(2) 10 μ, 250 × 10 mm; mobile phase, 4% ethanol in 20-mM NaH 2 PO 4 ; pH, 4.0; flow rate, 4 mL/min; and typical semi-preparative trace, Figure 1 ). The product peak (t R 20-25 min) was collected into the product collection vial with concomitant dilution into 0.9% sodium chloride for injection, USP, and sodium phosphates for injection, USP. The final formulation was then passed through a 0.22-μm filter into a 
Quality control of (À)-[ 18 F]flubatine
Quality control testing of (À)-[
18 F]flubatine was conducted using the guidelines outlined in the US Pharmacopeia using the standard tests previously described, 20 and results are reported in Table 1 . Testing included visual inspection, pH, chemical purity and radiochemical purity (RCP, see Analysis of Chemical Purity and Radiochemical Purity/Identity section), specific activity, residual solvent analysis, residual kryptofix analysis, sterile filter integrity, bacterial endotoxin analysis, and sterility testing.
Analysis of chemical purity and radiochemical purity/identity
Chemical and radiochemical purities/identities are analyzed using a Shimadzu LC2010 HPLC equipped with a radioactivity detector and an ultraviolet (UV) detector, and a representative analytical HPLC trace is shown (Figure 2 ). Radiochemical purity for doses must be >95%, and identity is confirmed by comparing the retention time of the radiolabeled product with that of the corresponding unlabeled reference standard. Column-Phenomonex Synergi Polar-RP 4 μ, 150 × 4.6 mm; mobile phase-50% acetonitrile : 50% 0.1-M acetic acid; pH, 4.5; 
Primate micropositron-emission tomography imaging
All animal studies were performed in accordance with the standards set by the University Committee on Use and Care of Animals (UCUCA) at the University of Michigan. Primate imaging studies (n = 3) were performed using a mature female rhesus monkey (weight = 5.8 kg). The monkey was anesthetized (isoflurane), intubated, and positioned in a Concorde MicroPET P4 scanner. Following a transmission scan was the injection of the animal intravenously with (À)-[ 18 F]flubatine (4-5 mCi (148-185 MBq)) as a bolus over 1 min. The collection of emission data was started with radiotracer injection, and the brain was imaged for 90 min (18 × 5-min frames). Image data were reconstructed using the 3-D maximum a posteriori algorithm (Figure 3 ). By using a summed image, regions of interest were drawn over sections of the brain (thalamus, cortex, striatum, and cerebellum), and time-radioactivity curves were calculated (Figure 4 ). For the displacement study, a 2.5-μg/kg dose of the selective α 4 β 2 nAChR agonist nifene was injected intravenously at 60 min after the radiotracer injection, and scanning continued until 90 min, and time-radioactivity curves were generated in an analogous fashion ( Figure 5 ).
Results and discussion
Synthesis of (À)-[ 18 F]flubatine
The original syntheses of (À)-[ 14, 16 This chemistry has proven suitable for the initial preclinical evaluation of the radiopharmaceutical 14, 15 and the first-in-man evaluation that has been recently reported. 17, 18 However, as we looked to make (À)-[ 18 F]flubatine available to our clinicians, we had cause to develop an entirely new synthesis more suitable for our synthesis equipment, by using the newly commercially available enantiomerically pure Boc-protected trimethylammonium salt precursor.
18 F]Flubatine was prepared according to Scheme 1, and as outlined in Synthesis of (-)-[18F]Flubatine section. Subjecting the Boc-protected trimethylammonium iodide precursor to our standard fluorination conditions resulted in high conversion (>95%) to Boc-protected (À)-[ 18 F]flubatine. As we wished to avoid using iodotrimethylsilane in our clinical synthesis modules, alternative strategies for removing the carbamate protecting group were evaluated. Aqueous hydrochloric acid (1 M) is our standard protocol for removal of Boc-protecting groups in fluorine-18 radiochemical reactions, and gratifyingly it worked well in this case too. Similar results were reported by Fischer and co-workers in their precursor matrix study. 19 A single semipreparative HPLC yielded (À)-[
18 F]flubatine, and the total synthesis time was about 60 min. Three consecutive syntheses were completed to qualify the synthetic method for clinical production of (À)-[ 18 F]fluoride, non-decay corrected, n = 3). The radiochemical purity was >95%, and specific activity was 4647 Ci/mmol (171.9 GBq/μmol) at EOS. Doses of (À)-[ 18 
F]
flubatine met all of the established release criteria as summarized in Table 1 and described earlier, confirming their suitability for use in clinical PET imaging of nAChRs.
Micropositron-emission tomography imaging in rhesus monkeys
With doses of (À)-[
18 F]flubatine available, we were interested in assessing the regional distribution and time-activity curves in the rhesus macaque brain. Following a transmission scan, the administration of the monkey, with 4-5 mCi (148-185 MBq) of (À)-[
18 F]flubatine, was performed, and it received a 90-min dynamic PET scan (18 × 5-min frames). Image data were reconstructed using the 3-D maximum a posteriori algorithm, and expected uptake in the thalamus, frontal cortex, and striatum, areas of the brain rich in α 4 β 2 nAChRs, was apparent ( Figure 3) .
By using a summed image, regions of interest were drawn over sections of the brain (thalamus, cortex, striatum, and cerebellum), and time-radioactivity curves were calculated. Uptake was normalized to injected dose and averaged for the three scans (Figure 4 ). Higher uptake and slower washout of (À)- [ 18 F]flubatine were observed in the thalamus than those in the other regions of the brain, which was expected and is consistent with previously reported data in piglets 14, 15 and humans. 17, 18 Peak uptake for the thalamus in the rhesus monkeys (45 min) was found to be faster than the reported peak uptake for piglets (80 min). Although no obvious explanation exists for this species difference, it does lend support to the recent suggestion that (À)- [ 18 F]flubatine kinetics will allow all kinetic parameters to be estimated from clinical PET data acquired over only 90 min. 17, 18 Finally, the injection of a 2.5-μg/kg dose of the selective α 4 β 2 nAChR agonist nifene 21 at 60 min initiated a slow washout of [ 18 F]flubatine from the thalamus, with about 25% clearance by the end of the imaging study at 90 min ( Figure 5 ).
Conclusion
In conclusion, a fully automated radiosynthesis of (À)- [ 18 F] flubatine has been established. Doses met all quality control criteria, confirming their suitability for application in clinical imaging. Evaluation of (À)- [ 18 F]flubatine in rhesus macaques revealed higher uptake and slower washout in the thalamus than those in the other areas of the brain, and the time-activity curves confirm that (À)- [ 18 F]flubatine has kinetics that will simplify PET imaging of α 4 β 2 nAChRs in a clinical setting. 
